Why BioXcel Therapeutics Stock Popped Today
Shares of BioXcel Therapeutics (NASDAQ: BTAI) jumped by as much as 14.4% on Monday -- and finished the trading session up 11.7% -- thanks to a Wall Street analyst making a bullish case for the biopharmaceutical company.
UBS analyst Colin Bristow initiated coverage of BioXcel Therapeutics' stock with a buy rating and a $99 price target. The company's shares are worth $51.72 apiece after today's rally. Why does Bristow see such huge potential upside for BioXcel Therapeutics'? The answer lies with the company's leading pipeline candidate, sublingual thin film BXCL501. In a phase 3 clinical trial, BXCL501 was shown to be effective in treating acute agitation in patients with schizophrenia and bipolar disorder.
Image source: Getty Images.
Source Fool.com
